HC Wainwright Reaffirms "Buy" Rating for Immunocore (NASDAQ:IMCR)

HC Wainwright reiterated their buy rating on shares of Immunocore (NASDAQ:IMCR - Free Report) in a research note issued to investors on Monday,Benzinga reports. The firm currently has a $100.00 price target on the stock.

A number of other equities analysts also recently commented on IMCR. Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. JPMorgan Chase & Co. reduced their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research note on Monday, April 14th. Mizuho reduced their target price on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Finally, Oppenheimer lifted their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Immunocore presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Trading Up 0.2%

NASDAQ:IMCR traded up $0.09 during trading hours on Monday, hitting $37.79. The company had a trading volume of 109,558 shares, compared to its average volume of 329,326. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The company has a 50-day moving average of $29.89 and a 200 day moving average of $30.12. The company has a market cap of $1.90 billion, a P/E ratio of -39.77 and a beta of 0.83. Immunocore has a 1 year low of $23.15 and a 1 year high of $43.35.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $125.13 million for the quarter, compared to the consensus estimate of $108.82 million. During the same period in the previous year, the firm earned ($0.49) earnings per share. Immunocore's quarterly revenue was up 33.6% compared to the same quarter last year. Sell-side analysts expect that Immunocore will post -0.94 earnings per share for the current year.

Insider Buying and Selling

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Immunocore

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in Immunocore during the 4th quarter worth approximately $25,000. Oppenheimer Asset Management Inc. purchased a new stake in Immunocore during the 1st quarter worth approximately $225,000. China Universal Asset Management Co. Ltd. increased its stake in Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after buying an additional 960 shares during the period. Checkpoint Capital L.P. purchased a new stake in Immunocore during the 1st quarter worth approximately $267,000. Finally, Banque Transatlantique SA purchased a new stake in Immunocore during the 1st quarter worth approximately $278,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.